Contemporary pre-clinical development of anticancer agents - What are the optimal preclinical models?

European Journal of Cancer

Volumn 45, Issue 16, 2009, Pages 2768-2781

  Damia, Giovanna ^a   D'Incalci, Maurizio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Anticancer drugs; In vivo models; Screening; Targeted therapy

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CYCLOPHOSPHAMIDE; DASATINIB; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; EVEROLIMUS; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GELDANAMYCIN; IMATINIB; LAPATINIB; PACLITAXEL; PANITUMUMAB; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RETINOIC ACID; SILIBININ; SORAFENIB; SUNITINIB; SUTEN; TEMSIROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; DRUG SCREENING; GENETIC MODEL; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; TUMOR BIOPSY; XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENETIC ENGINEERING; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; PIPERAZINES; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 70350034197     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.08.008     Document Type: Article

References (124)

1. Ma W.W., and Adjei A.A. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 59 (2009) 111-137
2. Morgan T.M., Koreckij T.D., and Corey E. Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9 (2009) 237-249
3. Hait W.N., and Hambley T.W. Targeted cancer therapeutics. Cancer Res 69 (2009) 1263-1267 [discussion 1267]
4. Rutkowski P., and Ruka W. Emergency surgery in the era of molecular treatment of solid tumours. Lancet Oncol 10 (2009) 157-163
5. Lorusso G., and Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130 (2008) 1091-1103
6. Suggitt M., and Bibby M.C. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11 (2005) 971-981
7. Holbeck S.L. Update on NCI in vitro drug screen utilities. Eur J Cancer 40 (2004) 785-793
8. Paull K.D., Shoemaker R.H., Hodes L., et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81 (1989) 1088-1092
9. Rajkumar S.V., Richardson P.G., Hideshima T., and Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23 (2005) 630-639
10. Sausville E.A., and Feigal E. Evolving approaches to cancer drug discovery and development at the National Cancer Institute, USA. Ann Oncol 10 (1999) 1287-1291
11. Friedrich J., Ebner R., and Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge?. Int J Radiat Biol 83 (2007) 849-871
12. Lin R.Z., and Chang H.Y. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. Biotechnol J 3 (2008) 1172-1184
13. Bryant H.E., Schultz N., Thomas H.D., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
14. Farmer H., McCabe N., Lord C.J., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
15. Sharma S.V., and Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21 (2007) 3214-3231
16. Damia G., and D'Incalci M. Targeting DNA repair as a promising approach in cancer therapy. Eur J Cancer 43 (2007) 1791-1801
17. Tavecchio M., Simone M., Erba E., et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 44 (2008) 609-618
18. Besancon R., Valsesia-Wittmann S., Puisieux A., de Fromentel C.C., and Maguer-Satta V. Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 16 (2009) 394-416
19. Marotta L.L., and Polyak K. Cancer stem cells: a model in the making. Curr Opin Genet Dev 19 (2009) 44-50
20. Finlan L.E., and Hupp T.R. Epidermal stem cells and cancer stem cells: insights into cancer and potential therapeutic strategies. Eur J Cancer 42 (2006) 1283-1292
21. Park C.Y., Tseng D., and Weissman I.L. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ther 17 (2009) 219-230
22. Blagosklonny M.V. Target for cancer therapy: proliferating cells or stem cells. Leukemia 20 (2006) 385-391
23. Simeone D.M. Pancreatic cancer stem cells: implications for the treatment of pancreatic cancer. Clin Cancer Res 14 (2008) 5646-5648
24. Decker S., Hollingshead M., Bonomi C.A., Carter J.P., and Sausville E.A. The hollow fibre model in cancer drug screening: the NCI experience. Eur J Cancer 40 (2004) 821-826
25. Hall L.A., Krauthauser C.M., Wexler R.S., Hollingshead M.G., Slee A.M., and Kerr J.S. The hollow fiber assay: continued characterization with novel approaches. Anticancer Res 20 (2000) 903-911
26. Suggitt M., Cooper P.A., Shnyder S.D., and Bibby M.C. The hollow fibre model-facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare. Int J Oncol 29 (2006) 1493-1499
27. Temmink O.H., Prins H.J., van Gelderop E., and Peters G.J. The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. Br J Cancer 96 (2007) 61-66
28. Venditti J.M., Wesley R.A., and Plowman J. Current NCI preclinical antitumor screening in vivo: results of tumor panel screening, 1976-1982, and future directions. Adv Pharmacol Chemother 20 (1984) 1-20
29. Kelland L.R. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer 40 (2004) 827-836
30. Talmadge J.E., Singh R.K., Fidler I.J., and Raz A. Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170 (2007) 793-804
31. Fiebig H.H., Maier A., and Burger A.M. Clonogenic assay with established human tumour xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 40 (2004) 802-820
32. Alley M.C., Scudiero D.A., Monks A., et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48 (1988) 589-601
33. Garber K. From human to mouse and back: 'tumorgraft' models surge in popularity. J Natl Cancer Inst 101 (2009) 6-8
34. Boven E., Winograd B., Berger D.P., et al. Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. Cancer Res 52 (1992) 5940-5947
35. Fiebig H.H., Berger D.P., Winterhalter B.R., and Plowman J. In vitro and in vivo evaluation of US-NCI compounds in human tumor xenografts. Cancer Treat Rev 17 (1990) 109-117
36. Sausville E.A., and Burger A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res 66 (2006) 3351-3354 [discussion 3354]
37. Steel G.G., Courtenay V.D., and Peckham M.J. The response to chemotherapy of a variety of human tumour xenografts. Br J Cancer 47 (1983) 1-13
38. Johnson J.I., Decker S., Zaharevitz D., et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 84 (2001) 1424-1431
39. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther 2 (2003) S134-S139
40. Valoti G., Nicoletti M.I., Pellegrino A., et al. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4 (1998) 1977-1983
41. Sessa C., De Braud F., Perotti A., et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 23 (2005) 1867-1874
42. Krasner C.N., McMeekin D.S., Chan S., et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 97 (2007) 1618-1624
43. Krasner C.N., Poveda A., Herzog T., et al. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: Results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol (2009) 27 [abstract 5526]
44. Bibby M.C. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40 (2004) 852-857
45. Hoffman R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17 (1999) 343-359
46. Killion J.J., Radinsky R., and Fidler I.J. Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17 (1998) 279-284
47. Hoffman R.M. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Methods Mol Med 111 (2005) 297-322
48. Kuo T.H., Kubota T., Watanabe M., et al. Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice. the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res 13 (1993) 627-630
49. Fidler I.J., Wilmanns C., Staroselsky A., Radinsky R., Dong Z., and Fan D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev 13 (1994) 209-222
50. Olive K.P., and Tuveson D.A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin Cancer Res 12 (2006) 5277-5287
51. Frese K.K., and Tuveson D.A. Maximizing mouse cancer models. Nat Rev Cancer 7 (2007) 645-658
52. Sharpless N.E., and Depinho R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5 (2006) 741-754
53. Robles A.I., and Varticovski L. Harnessing genetically engineered mouse models for preclinical testing. Chem Biol Interact 171 (2008) 159-164
54. Van Dyke T., and Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 108 (2002) 135-144
55. Singh M., and Johnson L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin Cancer Res 12 (2006) 5312-5328
56. Gutmann D.H., Hunter-Schaedle K., and Shannon K.M. Harnessing preclinical mouse models to inform human clinical cancer trials. J Clin Invest 116 (2006) 847-852
57. Varticovski L., Hollingshead M.G., Robles A.I., et al. Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models. Clin Cancer Res 13 (2007) 2168-2177
58. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97 (2000) 10173-10178
59. Brain J., Saksena A., and Laneuville P. The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice. Leuk Res 26 (2002) 1011-1016
60. Boolbol S.K., Dannenberg A.J., Chadburn A., et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 56 (1996) 2556-2560
61. Press M.F., and Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67 (2007) 2045-2075
62. Kung A.L. Practices and pitfalls of mouse cancer models in drug discovery. Adv Cancer Res 96 (2007) 191-212
63. Kornek G., and Selzer E. Targeted therapies in solid tumours: pinpointing the tumour's Achilles heel. Curr Pharm Des 15 (2009) 207-242
64. Shnyder S.D., Hasan J., Cooper P.A., et al. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature. Anticancer Res 25 (2005) 1889-1894
65. Riemann B., Schafers K.P., Schober O., and Schafers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 52 (2008) 215-221
66. Rowland D.J., and Cherry S.R. Small-animal preclinical nuclear medicine instrumentation and methodology. Semin Nucl Med 38 (2008) 209-222
67. Sundaram B., Quint L.E., Patel H.J., and Deeb G.M. CT findings following thoracic aortic surgery. Radiographics 27 (2007) 1583-1594
68. Villalobos V., Naik S., and Piwnica-Worms D. Current state of imaging protein-protein interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng 9 (2007) 321-349
69. Hwang do W., Kang J.H., Jeong J.M., et al. Noninvasive in vivo monitoring of neuronal differentiation using reporter driven by a neuronal promoter. Eur J Nucl Med Mol Imaging 35 (2008) 135-145
70. Rowley J.D. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243 (1973) 290-293
71. Lydon N.B., and Druker B.J. Lessons learned from the development of imatinib. Leuk Res 28 Suppl 1 (2004) S29-S38
72. Deininger M., Buchdunger E., and Druker B.J. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105 (2005) 2640-2653
73. Mauro M.J., O'Dwyer M., Heinrich M.C., and Druker B.J. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 20 (2002) 325-334
74. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
75. Tornillo L., and Terracciano L.M. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol 59 (2006) 557-563
76. Sleijfer S., Wiemer E., and Verweij J. Drug Insight: gastrointestinal stromal tumors (GIST)-the solid tumor model for cancer-specific treatment. Nat Clin Pract Oncol 5 (2008) 102-111
77. Hynes N.E., and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21 (2009) 177-184
78. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
79. Grunwald V., and Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95 (2003) 851-867
80. Laurent-Puig P., Lievre A., and Blons H. Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res 15 (2009) 1133-1139
81. Hopper-Borge E.A., Nasto R.E., Ratushny V., Weiner L.M., Golemis E.A., and Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 13 (2009) 339-362
82. Ji H., Li D., Chen L., et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell 9 (2006) 485-495
83. Maheswaran S., Sequist L.V., Nagrath S., et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359 (2008) 366-377
84. Allegra C.J., Jessup J.M., Somerfield M.R., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009) 2091-2096
85. Lievre A., Bachet J.B., Boige V., et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26 (2008) 374-379
86. De Roock W., Piessevaux H., De Schutter J., et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 19 (2008) 508-515
87. Cho H.S., Mason K., Ramyar K.X., et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421 (2003) 756-760
88. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353 (2005) 1659-1672
89. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353 (2005) 1673-1684
90. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
91. Pegram M., and Ngo D. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study. Adv Drug Deliv Rev 58 (2006) 723-734
92. Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89 (1992) 4285-4289
93. Arnould L., Gelly M., Penault-Llorca F., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 94 (2006) 259-267
94. Musolino A., Naldi N., Bortesi B., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26 (2008) 1789-1796
95. Cao Y. Tumor angiogenesis and molecular targets for therapy. Front Biosci 14 (2009) 3962-3973
96. Cao Y., and Langer R. A review of Judah Folkman's remarkable achievements in biomedicine. Proc Natl Acad Sci USA 105 (2008) 13203-13205
97. Ribatti D. The discovery of antiangiogenic molecules: a historical review. Curr Pharm Des 15 (2009) 345-352
98. Cao Y. Molecular mechanisms and therapeutic development of angiogenesis inhibitors. Adv Cancer Res 100 (2008) 113-131
99. D'Onofrio A., and Gandolfi A. A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. Math Med Biol 26 (2009) 63-95
100. Taraboletti G., and Giavazzi R. Modelling approaches for angiogenesis. Eur J Cancer 40 (2004) 881-889
101. MacDonald I.C., and Chambers A.F. Chapter 9. Intravital videomicroscopy in angiogenesis research. Methods Enzymol 444 (2008) 201-230
102. Vargas A., Zeisser-Labouebe M., Lange N., Gurny R., and Delie F. The chick embryo and its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems. Adv Drug Deliv Rev 59 (2007) 1162-1176
103. Dalal S., and Burchill S.A. Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours. Eur J Cancer 45 (2009) 713-722
104. Lee F.Y., Covello K.L., Castaneda S., et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 14 (2008) 8123-8131
105. Ogata T., Kurabayashi M., Maeno T., et al. An angiogenesis inhibitor TNP-470 (AGM-1470) suppresses vascular smooth muscle cell proliferation in experimental rat aortotomy models. J Cardiovasc Surg (Torino) 45 (2004) 497-500
106. Zhang C., Yan Z., Arango M.E., Painter C.L., and Anderes K. Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 15 (2009) 238-246
107. Brown J.Q., Wilke L.G., Geradts J., Kennedy S.A., Palmer G.M., and Ramanujam N. Quantitative optical spectroscopy: a robust tool for direct measurement of breast cancer vascular oxygenation and total hemoglobin content in vivo. Cancer Res 69 (2009) 2919-2926
108. Fox S.B. Assessing tumor angiogenesis in histological samples. Methods Mol Biol 467 (2009) 55-78
109. Feng Y., Jeong E.K., Mohs A.M., Emerson L., and Lu Z.R. Characterization of tumor angiogenesis with dynamic contrast-enhanced MRI and biodegradable macromolecular contrast agents in mice. Magn Reson Med 60 (2008) 1347-1352
110. Mullighan C.G., and Downing J.R. Global genomic characterization of acute lymphoblastic leukemia. Semin Hematol 46 (2009) 3-15
111. Fox E.J., Salk J.J., and Loeb L.A. Cancer genome sequencing-an interim analysis. Cancer Res 69 (2009) 4948-4950
112. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
113. Fichtner I., Slisow W., Gill J., et al. Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas. Eur J Cancer 40 (2004) 298-307
114. He L.Z., Guidez F., Tribioli C., et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18 (1998) 126-135
115. Lobell R.B., Omer C.A., Abrams M.T., et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61 (2001) 8758-8768
116. Kohl N.E., Omer C.A., Conner M.W., et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med 1 (1995) 792-797
117. Omer C.A., Chen Z., Diehl R.E., et al. Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res 60 (2000) 2680-2688
118. Politi K., Zakowski M.F., Fan P.D., Schonfeld E.A., Pao W., and Varmus H.E. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. Genes Dev 20 (2006) 1496-1510
119. Fujishita T., Aoki K., Lane H.A., Aoki M., and Taketo M.M. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA 105 (2008) 13544-13549
120. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J Clin Oncol 23 (2005) 939-952
121. Singh R.P., Raina K., Sharma G., and Agarwal R. Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice. Clin Cancer Res 14 (2008) 7773-7780
122. Isayeva T., Chanda D., Kallman L., Eltoum I.E., and Ponnazhagan S. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model. Cancer Res 67 (2007) 5789-5797
123. Cao X., Jia G., Zhang T., et al. Non-invasive MRI tumor imaging and synergistic anticancer effect of HSP90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model. Cancer Chemother Pharmacol 62 (2008) 985-994
124. Chesler L., Goldenberg D.D., Seales I.T., et al. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res 67 (2007) 9435-9442